Prof. Franck Pagès, immunologist at the Georges Pompidou European Hospital, discusses the role of immunology in personalized medicine. Immunotherapeutic clinical trials have been in full swing for the last ten years. These immunotherapies aim to stimulate the natural immune response of patients against cancer. What comes out of these studies is the importance of better understanding the subject’s natural immunity in order to better select them to increase the percentage of patients responding to immunotherapies. In the future, the idea would be to combine the immunotherapies between them or to supplement them with conventional strategies targeting the tumor cell.